Meeting
2019 ASCO Annual Meeting
A phase I study evaluating COM701 in patients with advanced solid tumors.
Authors
Drew W. Rasco
South Texas Accelerated Research Therapeutics (START), San Antonio, TX
Drew W. Rasco , Daniel A. Vaena , Ryan J. Sullivan , Jason J. Luke , Adam ElNaggar , John Hunter , Adeboye H. Adewoye , Judy Olweny , Amita Patnaik , Erika Paige Hamilton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03667716
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2657)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2657
Abstract #
TPS2657
Poster Bd #
294b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I study evaluating COM701 in patients with advanced solid tumors.
First Author: Drew W. Rasco
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I study evaluating COM701 monotherapy and in combination with nivolumab in patients with advanced solid malignancies.
First Author: Ryan J. Sullivan
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2023 ASCO Annual Meeting
Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.
First Author: Mirella Nardo